Compare EDAP & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDAP | NKTX |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 168.2M |
| IPO Year | 1998 | 2020 |
| Metric | EDAP | NKTX |
|---|---|---|
| Price | $3.41 | $2.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.00 | ★ $11.33 |
| AVG Volume (30 Days) | 39.8K | ★ 539.7K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,527,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.63 | N/A |
| 52 Week Low | $1.21 | $1.48 |
| 52 Week High | $5.05 | $2.81 |
| Indicator | EDAP | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 52.12 |
| Support Level | $1.98 | $1.95 |
| Resistance Level | $3.44 | $2.32 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 29.35 | 70.97 |
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.